Compare QNCX & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QNCX | MDXH |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.0M | 167.8M |
| IPO Year | 2019 | 2021 |
| Metric | QNCX | MDXH |
|---|---|---|
| Price | $2.81 | $3.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $7.67 | $7.67 |
| AVG Volume (30 Days) | ★ 698.3K | 120.7K |
| Earning Date | 11-12-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $103,069,000.00 |
| Revenue This Year | N/A | $23.34 |
| Revenue Next Year | N/A | $22.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.68 |
| 52 Week Low | $0.72 | $1.35 |
| 52 Week High | $4.55 | $5.33 |
| Indicator | QNCX | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 38.83 | 39.88 |
| Support Level | $3.18 | $3.20 |
| Resistance Level | $3.38 | $3.58 |
| Average True Range (ATR) | 0.27 | 0.20 |
| MACD | -0.17 | 0.02 |
| Stochastic Oscillator | 6.51 | 26.00 |
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.